NICE issues 2nd draft guidance on Pixuvri (Cell Therapeutics)
NICE has issued second draft guidance on Pixuvri (pixantrone), from Cell Therapeutics, as a treatment of adult patients with multiply relapsed or refractory aggressive B-cell Non-Hodgkin Lymphoma (aggressive B-cell NHL). It concluded that an initial patient access scheme approved by the Department of Health in July 2013 does not overcome the uncertainties in the evidence for pixantrone's clinical effectiveness and once again requests that consultees, including CTI, healthcare professionals and members of the public, comment on the draft guidance. Consultation will close on November 4 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins